A Phase II Study of 131 I-rituximab for Patients With Relapsed or Refractory Marginal Zone Lymphoma.
Yoon Jung JangSang Moo LimInki LeeByung Hyun ByunIlhan LimByung Il KimChang Woon ChoiSeung-Sook LeeSung Hyun YangIm Il NaHyo-Rak LeeDong-Yeop ShinHye Jin KangPublished in: Clinical Medicine Insights. Oncology (2023)
I-rituximab showed marked efficacy in patients with relapsed or refractory marginal zone lymphoma, with a considerable risk of secondary malignancies during long-term follow-up. Radioimmunotherapy is not a recommended treatment option for relapsed or refractory marginal zone lymphoma but may be considered when other treatment options are not feasible.